Welcome to our dedicated page for WW International news (Ticker: WW), a resource for investors and traders seeking the latest updates and insights on WW International stock.
WW International, Inc. operates the Weight Watchers weight-management platform through digital, workshop and clinical subscription offerings. Company news commonly covers subscriber trends, subscription revenue, adjusted operating measures and the balance between its Behavioral business and its Clinical business.
Recurring updates also include expansion of the Med+ clinical offering, access to FDA-approved GLP-1 treatment options through affiliated medical groups, debt-reduction actions involving its term loan, and governance changes such as board appointments, committee assignments and interim executive-leadership structure.
Weight Watchers (Nasdaq: WW) reported Q1 2026 results for the quarter ended March 31, 2026. Total End of Period Subscribers were 2.7 million and End of Period Clinical Subscribers were 197 thousand (+46% YoY). Revenue was $168 million and Clinical Subscription Revenue was $39 million (+32% YoY). Q1 Net Loss was $52.0 million; Q1 Adjusted EBITDA was a loss of $1.8 million. Cash was $121 million. The company reaffirmed full-year 2026 guidance of $620–$635 million revenue and $105–$115 million Adjusted EBITDA, and announced debt prepayment actions expected to reduce term loan principal by $42 million and annual interest by ~$4 million.
Weight Watchers (NASDAQ: WW) will add the FDA-approved Ozempic pill (semaglutide) to its Med+ formulary effective May 1, 2026, giving adults with type 2 diabetes a once-daily oral GLP-1 option. The program includes board-certified clinician care, insurance navigation, a diabetes support program, and a reported 0.75% HbA1c reduction at six months in 136 participants.
Weight Watchers (NASDAQ: WW) intends to use up to $40 million of cash to prepay and reduce the principal on its outstanding term loan.
The plan includes $25M–$30M to cover the annual cash sweep due June 24, 2026, plus a voluntary solicitation to prepay up to $10M at a discount, running April 27–30, 2026. The company reaffirmed Q1 2026 end-of-period subscriber estimates and full-year 2026 financial guidance, and expects positive cash generation after first-quarter seasonal marketing use.
WW (NASDAQ: WW) will report Q1 2026 results for the period ended March 31, 2026, before market open on Thursday, May 7, 2026.
A conference call is scheduled for 8:30 a.m. ET the same day with a live webcast and a replay available on the company's Events and Presentations page for at least 90 days.
Weight Watchers (Nasdaq: WW) appointed Heather Thiltgen to its Board of Directors, effective April 20, 2026. Ms. Thiltgen is president of Presbyterian Health Plan and previously led WellSense Health Plan. The Board expanded to six independent members; she joins the Compensation and Benefits Committee and is expected to stand for election at the 2026 annual meeting.
Her expertise includes expanding access to GLP-1 therapies, navigating payor-provider regulation, rebuilding membership bases, and scaling telehealth and pharmaceutical solutions.
WW (NASDAQ: WW) will offer Eli Lilly’s newly FDA-approved oral GLP-1 Foundayo (orforglipron) through its Med+ program beginning April 9, 2026. Med+ members gain access to once-daily, oral treatment with board-certified clinician care, insurance support, and the Weight Watchers GLP-1 Success behavioral program.
Self-pay pricing for Foundayo starts at $149 per month for the lowest dose, with price varying by dose. Weight Watchers reports members who engaged the GLP-1 Success Program for 12 months lost 29.1% more body weight on average than non-engaged members.
WW (Nasdaq: WW) announced updates to its Board committee composition after appointing Lisa Gavales and Sue Gove as independent directors on April 9, 2026. Committee chairs and members were named for Audit, Compensation and Benefits, Nominating and Corporate Governance, and Strategy and Finance.
The Board confirmed the Office of the CEO will remain led by the existing Transition Committee—CFO Felicia DellaFortuna and COO Jon Volkmann—with counsel from the new directors, and decided not to appoint an interim CEO while a permanent CEO search continues with an executive search firm.
Weight Watchers (Nasdaq: WW) appointed Lisa Gavales and Sue Gove as independent directors, effective April 7, 2026. Following the appointments the Board totals six directors, all independent. Both bring consumer, digital and senior leadership experience to support the company’s strategic transformation and member-acquisition efforts.
Ms. Gavales adds e-commerce and brand-engagement expertise; Ms. Gove contributes CEO/COO/CFO experience and public-board experience. Both will serve until the 2026 annual meeting and are expected to stand for election.
Weight Watchers (Nasdaq: WW) announced a leadership transition effective April 3, 2026, after Tara Comonte’s departure on March 31, 2026. The Board formed a Transition Committee and established an Office of the CEO led by CFO Felicia DellaFortuna and COO Jon Volkmann while conducting a CEO search.
The company appointed Debra Cotter as chief legal officer and secretary effective April 10, 2026, and noted director resignations. Weight Watchers reaffirmed its Q1 2026 subscriber estimates and full‑year 2026 financial guidance.
Weight Watchers (NASDAQ: WW) expanded collaboration with Novo Nordisk to offer Med+ members subscription pricing for Wegovy, promising the lowest available self-pay prices and up to $1,200 annual savings.
Eligible members can pre-pay for 3, 6, or 12 months, with discounts on pens and pills and access to Wegovy across multiple doses.